VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,079,599 | -21.1% | 60,408 | -22.7% | 0.00% | 0.0% |
| Q2 2023 | $3,904,810 | +100.7% | 78,190 | +50.6% | 0.00% | 0.0% |
| Q1 2023 | $1,945,437 | +924.3% | 51,906 | +1210.4% | 0.00% | – |
| Q4 2022 | $189,930 | +427.6% | 3,961 | +162.5% | 0.00% | – |
| Q3 2022 | $36,000 | -12.2% | 1,509 | -20.0% | 0.00% | – |
| Q2 2022 | $41,000 | -56.8% | 1,886 | -52.2% | 0.00% | – |
| Q1 2022 | $95,000 | -77.6% | 3,949 | -77.9% | 0.00% | – |
| Q4 2021 | $425,000 | +5971.4% | 17,859 | +6210.6% | 0.00% | – |
| Q3 2021 | $7,000 | -22.2% | 283 | -30.6% | 0.00% | – |
| Q2 2021 | $9,000 | -98.7% | 408 | -98.8% | 0.00% | – |
| Q1 2021 | $676,000 | -28.8% | 34,252 | -4.1% | 0.00% | – |
| Q4 2020 | $949,000 | +39.4% | 35,721 | +158.9% | 0.00% | – |
| Q3 2020 | $681,000 | – | 13,797 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |